Baccalaureat, Université de Rennes France, Experimental Sciences
Doctorat d’Etat (Doctorate with Thesis), Université de Rennes France, Médecine
Post Doctorate Fellowship, Harvard University and Massachussetts General Hospital, Neuro-immunology
Recent Publications:
  •    Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP. Frequency and Magnitude of Interferon β Neutralizing Antibodies in the Evaluation of Interferon β Immunogenicity in Patients with Multiple Sclerosis. J Interferon Cytokine Res. 2011 Jan 12. [Epub ahead of print].
  • Comi G, O’Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010 Feb;16(2):197-207.
  • Oger J, AlKhawajah M. Where are we going with drugs to treat MS? Will cost continue to increase? Can J Neurol Sci. 2010 May;37(3):305-8.
  • Kingwell E, Leung AL, Roger E, Duquette P, Rieckmann P, Tremlett H; UBC MS Neurologists. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci. 2010 May 15;292(1-2):57-62.
  • Koch M, Zhao Y, Yee I, Guimond C, Kingwell E, Rieckmann P, Sadovnick D, Tremlett H; UBC MS Clinic Neurologists. Disease onset in familial and sporadic primary progressive multiple sclerosis. Mult Scler. 2010 Jun;16(6):694-700.
  • Laule C, Vavasour IM, Zhao Y, Traboulsee AL, Oger J, Vavasour JD, Mackay AL, Li DK. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. Mult Scler. 2010 Jun;16(6):670-7.
  • Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 8;74(23):1877-85.
  • Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010 Jul;133(Pt 7):1900-13.
  • Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 Jul;9(7):740-50.
  • Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A; Investigators of the 16-year Long-Term Follow-Up Study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):907-12.
  • Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):494-502.
  • Laule C, Vavasour IM, Leung E, Li DK, Kozlowski P, Traboulsee AL, Oger J, Mackay AL, Moore GW. Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology. Mult Scler. 2010 Oct 21. [Epub ahead of print].
  • Oger J, Alkhajawah M. CCSVI: hope, hype or snake oil? Can J Neurol Sci. 2010 Nov;37(6):716. 5.
  • Chan S, Kingwell E, Oger J, Yoshida E, Tremlett H. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: A longitudinal study. Mult Scler. 2010 Dec 10.
  • Vavasour IM, Laule C, Li DK, Oger J, Moore GR, Traboulsee A, MacKay AL Longitudinal changes in myelin water fraction in two MS patients with active disease.. J Neurol Sci. 2009 Jan 15;276(1-2):49-53.
  • Soliven, E,  K Rezania, B Gundogdu,,  J Oger, B. Arnason, MD Terbutaline in myasthenia: a pilot study. J. neurol Sc. 2009 Feb 15;277(1-2):150-4.
  • Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman MS, Panitch H, Arnold DL, Vollmer T. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Multiple Sclerosis 2009 (Aug) 15(8) 959-964.
  • Freeman HJ, Gillett HR, Gillett PM, Oger J.  Adult celiac disease with acetylcholine receptor antibody positive myasthenia gravis. World J Gastroenterol. 2009 Oct 14;15(38):4741-4.
  • Cohen BA, Oger J, Gagnon A, Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci. 2008 Dec 15;275(1-2):7-17. Epub 2008 Sep 25.
  • Forwell SJ, Burnham S, Tremlett H, Morrisson WJ, Oger J. Primary and non-Primary fatigue in multiple sclerosis. Int J. of MS Care 2008;10:14-20.
  • Gibbs E, Oger J. A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. J Interferon Cytokine Res. 2008 Dec;28(12):713-23.
  • Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.  J Immunol Methods. 2008 Jul 31;336(2):113-8.  Epub 2008 May 1.
  • Liu Y, Li P., J. Lu, W. Xiong, J. Oger , J. Tetzlaff, M. Cynader Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis,” Journal of Immunology 2008 Aug 1 181 (3):1887-1897.
  • Rieckmann P, Traboulsee A, Devonshire V, Oger J.   Escalating immunotherapy of multiple sclerosis.  Therapeutic Advances in Neurology 2008; 1:181-192.
  • Tremlett HL, Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler, 2008 Jan;14(1):94-105. Epub 2007 Sep 19.
  • Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger, J, Prive M, Rhodes S, Robinson WH, Shi FD, UtzPJ, Valone F, Weiner L, Steinman L, Garren H. Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization with DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controll Phase ½ Trial. Arch Neurol 2007; 64(10):1407-1410.
  • Boz C, Oger J, Gibbs, Grossberg SE; the Neurologists of the UBC MS Clinic.  Reduced effectiveness of long-term interferon-(beta) treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.  Mult Scler. 2007 Nov;13(9):1127-1137.
  • Gibbs E, Oger J.  The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients.  J. Neuroimmunol. 2007;190(1-2):146-150.
  • Goodin DS, Frohman EM, Hurwitz B, O’Connor PW, Oger J, Reder AT, Stevens JC.  Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology.2007 Mar 27;68(13):977-84. Erratum in: Neurology. 2007 Aug 14;69(7):712.
  • Kister I, Herbert J, Swerdlow ML, Bergamaschi R, Piccolo G, Oger J.  Occurrence of CNS demyelinating disease in patients with myasthenia gravis.  Neurology. 2007 Apr 17;68(16):1326-7; author reply 1327.
  • Massart C, Gibassier J, Oger J, Le Page E, Edan G. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.  Clin Chim Acta. 2007 Feb;377(1-2):185-91. Epub 2006 Sep 30. Erratum in: Clin Chim Acta. 2007 May 1;380(1-2):255.
  • Oger J.  HTLV-1 infection and the viral etiology of multiple sclerosis. J Neurol Sci. 2007 Nov 15;262(1-2):100-4.
  • Oger J. Immunosuppression: promises and failures. J Neurol Sci. 2007 Aug 15;259(1-2):74-8. Epub 2007 Mar 23.
  • Tremlett HL, Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler. 2007 Oct 17; [Epub ahead of print], 2008;14(1):94-105.
  • Basile E, Gibbs E, Aziz T, Oger J.  During Long term treatment with glatiramer Acetate Specific antibodies switch from IgG1 to IgG4. J. Neuroimmunology. 2006 Aug;177(1-2):161-6.
  • De Castro-Costa CM, AQC Araújo, M Menna-Barreto, OM Takayanagui, M Pucioni-Sohler , Leitao E, SMB de Paula, R. Ishak, JG Ribas, L. Cartier, H Carton, E Gotuzzo, W Hall, S Montano, EL Murphy, J.Oger, C Remondegui, G. Taylor.  Proposals for Staging Diagnostic Criteria for Tropical Spastic Paraparesis/HTLV-l Associated Myelopathy (TSP/HAM). AIDS Research and Human Retroviruses. 2006. Oct;22(10):931-5.
  • Ebers GC, Kukay K, Bulman DR, Sadovnick AD, Rice G, Anderson C, Armstrong H.  Cousin K, Bell RB et al:  A full genome search in multiple sclerosis.  Nat Genet. 2006 Aug: 13(4):472-476.
  • Kister I, S. Gulati, C. Boz, J Oger, R. Bergamaschi, G. Piccolo, M.L Swerdlow. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Archives of Neurology. 2006 Jun;63(6):851-6.
  • Oger J and E. Gibbs.  Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis. Nature. (Neurology) 2006;2(2):76-77.
  • Toth C, McDonald D, Oger J and Brownell K. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol Scand 2006: Aug 114(2):124-32.
  • Tremlett, H, Silke Seemüller, Yinshan Zhao, Eric Yoshida, J Ogerand J. Petkau, Liver test abnormalities in multiple sclerosis: findings from placebo treated patients. Neurology. 2006;67:1291-1293.